[go: up one dir, main page]

WO2003066830A3 - Anticorps monoclonaux humains diriges contre des proteines membranaires - Google Patents

Anticorps monoclonaux humains diriges contre des proteines membranaires Download PDF

Info

Publication number
WO2003066830A3
WO2003066830A3 PCT/US2003/003763 US0303763W WO03066830A3 WO 2003066830 A3 WO2003066830 A3 WO 2003066830A3 US 0303763 W US0303763 W US 0303763W WO 03066830 A3 WO03066830 A3 WO 03066830A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane proteins
monoclonal antibodies
screening
antibodies against
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/003763
Other languages
English (en)
Other versions
WO2003066830A2 (fr
Inventor
Shaobing Hua
Michelle H Pauling
Li Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetastix Corp
Original Assignee
Genetastix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/072,031 external-priority patent/US6766082B2/en
Priority claimed from US10/071,866 external-priority patent/US20030165988A1/en
Application filed by Genetastix Corp filed Critical Genetastix Corp
Priority to AU2003209059A priority Critical patent/AU2003209059A1/en
Publication of WO2003066830A2 publication Critical patent/WO2003066830A2/fr
Anticipated expiration legal-status Critical
Publication of WO2003066830A3 publication Critical patent/WO2003066830A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de criblage efficaces à haut rendement de banques d'anticorps dirigés contre des cibles protéiques, notamment des protéines membranaires. Cette invention concerne plus particulièrement des procédés de criblage d'une banque d'anticorps entièrement humains dirigés contre des protéines membranaires telles que des récepteurs de la chimiokine dans des levures. De manière plus particulière, on crible une banque d'anticorps monocaténaires humains dirigés contre des fragments peptidiques dérivés respectivement de domaines extracellulaires de CXCR4 et CCR5 humains et on sélectionne des anticorps monoclonaux à haute affinité dirigés contre CXCR4 et CCR5. Ces anticorps peuvent être utilisés en tant qu'agents prophylactiques ou thérapeutiques pour prévenir et traiter l'infection par le VIH, le cancer et d'autres maladies ou pathologies, ainsi que pour cribler des médicaments et diagnostiquer des maladies ou des pathologies associées aux interactions avec les protéines membranaires.
PCT/US2003/003763 2002-02-08 2003-02-07 Anticorps monoclonaux humains diriges contre des proteines membranaires Ceased WO2003066830A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003209059A AU2003209059A1 (en) 2002-02-08 2003-02-07 Human monoclonal antibodies against membrane proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/072,031 US6766082B2 (en) 2000-10-18 2002-02-08 Waveguide-type optical device and manufacturing method therefor
US10/071,866 US20030165988A1 (en) 2002-02-08 2002-02-08 High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US10/071,866 2002-02-08
US10/072,031 2002-02-08
US13397802A 2002-04-25 2002-04-25
US10/133,978 2002-04-25

Publications (2)

Publication Number Publication Date
WO2003066830A2 WO2003066830A2 (fr) 2003-08-14
WO2003066830A3 true WO2003066830A3 (fr) 2009-06-18

Family

ID=27738990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003763 Ceased WO2003066830A2 (fr) 2002-02-08 2003-02-07 Anticorps monoclonaux humains diriges contre des proteines membranaires

Country Status (2)

Country Link
AU (1) AU2003209059A1 (fr)
WO (1) WO2003066830A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766017B1 (fr) * 2004-06-10 2015-01-21 Viventia Bio Inc. Anticorps specifique d'une tumeur
WO2006068646A1 (fr) * 2004-12-20 2006-06-29 Xiaoming Chen Méthodes d'identification et d'isolement d'anticorps spécifiques d'un épitope
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2643744A1 (fr) 2006-02-27 2007-08-30 Technische Universitaet Muenchen Imagerie et traitement du cancer
CA2658474A1 (fr) 2006-08-17 2008-02-21 F.Hoffmann-La Roche Ag Conjugue d'un anticorps dirige contre le ccr5 et peptide antifusiogene
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2074147B1 (fr) 2006-09-29 2012-03-21 F. Hoffmann-La Roche AG Anticorps diriges contre le ccr5 et leurs utilisations
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
TW200902544A (en) 2007-03-13 2009-01-16 Hoffmann La Roche Peptide-complement conjugates
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
BRPI0916973A2 (pt) * 2008-08-18 2016-07-26 Amgen Fremont Inc anticorpos para ccr2
EA201100943A1 (ru) 2008-12-16 2012-05-30 Новартис Аг Системы дрожжевого дисплея
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2011117423A1 (fr) 2010-03-26 2011-09-29 Ablynx N.V. Domaines variables uniques de l'immunoglobuline dirigés contre cxcr7
US20150158948A9 (en) 2011-03-28 2015-06-11 Francis Descamps Bispecific anti-cxcr7 immunoglobulin single variable domains
CN102323423A (zh) * 2011-05-31 2012-01-18 昆明理工大学 检测曲妥珠影响MCF-7细胞中Trx-1蛋白表达的方法
WO2012178137A1 (fr) 2011-06-24 2012-12-27 Gillies Stephen D Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
EP2970438A4 (fr) 2013-03-15 2016-08-24 Salimetrics Llc Anticorps monoclonal de mélatonine, détection, procédés et utilisations de celui-ci
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN112646833A (zh) * 2020-11-05 2021-04-13 杭州阿诺生物医药科技有限公司 一种全人源抗体酵母展示技术的设计与构建
US20240327822A1 (en) * 2021-08-12 2024-10-03 The University Of Hong Kong Materials and methods to comprehensively define adaptive immune responses
CN116731165B (zh) * 2023-03-23 2024-08-13 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
WO1999028502A1 (fr) * 1997-11-28 1999-06-10 Invitrogen Corporation Reactifs de fusion d'anticorps monoclonal a chaine unique regulant une transcription in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
WO1999028502A1 (fr) * 1997-11-28 1999-06-10 Invitrogen Corporation Reactifs de fusion d'anticorps monoclonal a chaine unique regulant une transcription in vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UEDA M.: "Genetic immobilization of proteins on the yeast cell surface", BIOTECHNOLOGY ADVANCES, vol. 18, 2000, pages 121 - 140, XP004205315, DOI: doi:10.1016/S0734-9750(00)00031-8 *

Also Published As

Publication number Publication date
WO2003066830A2 (fr) 2003-08-14
AU2003209059A8 (en) 2009-07-30
AU2003209059A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2003066830A3 (fr) Anticorps monoclonaux humains diriges contre des proteines membranaires
Wagner et al. The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation‐dependent up‐regulation and regulatory function
CN101045161B (zh) P-选择素糖蛋白配体1的调节剂
WO2003060090A3 (fr) Nouveau ligand de cytokine zcytor17
AU2555297A (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
EP3636667A3 (fr) Structures immunorégulatrices à partir de protéines naturellement produites
EP2062047B1 (fr) Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
Berhani et al. Human anti‐NKp46 antibody for studies of NKp46‐dependent NK cell function and its applications for type 1 diabetes and cancer research
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
Mazor et al. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
IL116617A0 (en) Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
Crescioli et al. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology
JP2007277263A (ja) カルボキシメチル化タンパク質に対する抗体
Boshuizen et al. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2)
RU94046414A (ru) Моноклональные антитела к гликопротеину р, их получение и применение, продуцирующие их клетки, иммунологический диагностический набор на их основе, терапевтический состав
US20230194545A1 (en) Antibodies that specifically bind peptides associated with the primary immunodeficiencies: wiskott-aldrich syndrome and x-linked agammaglobulinemia
CA3248965A1 (fr) Anticorps anti-b7-h7 ou fragment de liaison à l'antigène de celui-ci, son procédé de préparation et son utilisation
WO2004081033A3 (fr) Synthese de proteines au moyen d'une expression proteique exempte de cellule
Basset-Seguin et al. C3d, g is present in normal human epidermal basement membrane.
EP2192407A3 (fr) Procédé de détection d'immunité cellulaire et application associée aux médicaments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP